Advancements in AAV-mediated Gene Therapy for Pompe Disease

Pompe disease (glycogen storage disease type II) is caused by mutations in acid α-glucosidase (GAA) resulting in lysosomal pathology and impairment of the muscular and cardio-pulmonary systems. Enzyme replacement therapy (ERT), the only approved therapy for Pompe disease, improves muscle function by...

Descripción completa

Detalles Bibliográficos
Autores principales: Salabarria, S.M., Nair, J., Clement, N., Smith, B.K., Raben, N., Fuller, D.D., Byrne, B.J., Corti, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029369/
https://www.ncbi.nlm.nih.gov/pubmed/31796685
http://dx.doi.org/10.3233/JND-190426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029369/
https://www.ncbi.nlm.nih.gov/pubmed/31796685
http://dx.doi.org/10.3233/JND-190426

Ejemplares similares